Proteomics
Proteomics Led Target Discovery
Synairgen is using proteomic approaches to perform protein expression profiling on epithelial secretions obtained from tissue models using clinical samples obtained from donors without or with asthma. Proteomic approaches used include Surface Enhanced Laser Desorption Ionisation (SELDI), Gel-LC-MS/MS and Multi-Dimensional Liquid Chromatography (MDLC) and Q-TOF MS/MS.
How does proteomics work?
Proteomics enables the identification of protein differences between disease states. The 'time of flight' of proteins is dependant on their mass, which allows detection of many proteins. |
Protein profiles of epithelial secretions collected from our in vitro our models have been compared to identify novel drug ‘targets’ with altered expression in asthma vs healthy control samples. Identification of disease-relevant protein targets will support our drug target pipeline for evaluation and validation |
Status of proteomics programme
A number of differentially expressed protein targets have been isolated from secretions obtained from in vitro differentiated normal and asthmatic bronchial epithelial cells. We have observed a number of secreted proteins which are altered at baseline in asthma. The purification, validation and identification of these protein targets are in progress. Potential key drug targets will be functionally validated to generate a pipeline of drug targets for further development. |
